Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <= 30%

Simple item page
dc.contributor.authorPitt, B
dc.contributor.authorGheorghiade, M
dc.contributor.authorZannad, F
dc.contributor.authorAnderson, JL
dc.contributor.authorvan Veldhuisen, DJ
dc.contributor.authorParkhomenko, A
dc.contributor.authorCorbalan, R
dc.contributor.authorKlug, EQ
dc.contributor.authorMukherjee, R
dc.contributor.authorSolomon, H
dc.contributor.authorEPHESUS Invest
dc.date.accessioned2024-01-10T13:12:54Z
dc.date.available2024-01-10T13:12:54Z
dc.date.issued2006
dc.description.abstractAims: Because of the prognostic importance of LV dysfunction following an AMI and the increasing use of electrical and/or mechanical interventions in patients with LV systolic dysfunction, this retrospective analysis of EPHESUS patients with LVEF <= 30% at baseline was conducted to determine the value of eplerenone in this setting.
dc.description.abstractMethods and results: In EPHESUS, 6632 patients with LVEF <= 40% and clinical heart failure (HF) post-AMI who were receiving standard therapy were randomized to eplerenone 25 mg/day titrated to 50 mg/day or placebo for a mean follow-up of 16 months. Treatment with eplerenone in the subgroup of patients with LVEF <= 30% (N = 2106) resulted in relative risk reductions of 21% versus placebo in both all-cause mortality (P=0.012) and cardiovascular (CV) mortality/CV hospitalization (P=0.001), and 23% for CV mortality (P=0.008). The relative risk of sudden cardiac death (SCD) was reduced 33% (P=0.01) and HF mortality/HF hospitalization was reduced 25% (P=0.005) with eplerenone compared with placebo. Within 30 days of randomization, eplerenone resulted in relative risk reductions of 43% for all-cause mortality (P=0.002), 29% for CV mortality/CV hospitalization (P=0.006), and 58% for SCD (P=0.008).
dc.description.abstractConclusions: Treatment with eplerenone plus standard therapy in patients with post-AMI HF and LVEF <= 30% provided significant incremental benefits in reducing both early and late mortality and morbidity. (c) 2005 European Society of Cardiology Published by Elsevier B.V. All rights reserved.
dc.fechaingreso.objetodigital2024-04-16
dc.format.extent7 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.ejheart.2005.11.008
dc.identifier.issn1388-9842
dc.identifier.pubmedidMEDLINE:16504579
dc.identifier.urihttps://doi.org/10.1016/j.ejheart.2005.11.008
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/78243
dc.identifier.wosidWOS:000238089400012
dc.information.autorucMedicina;Corbalán R;S/I;98700
dc.issue.numero3
dc.language.isoen
dc.nota.accesocontenido completo
dc.pagina.final301
dc.pagina.inicio295
dc.publisherELSEVIER SCIENCE BV
dc.revistaEUROPEAN JOURNAL OF HEART FAILURE
dc.rightsacceso abierto
dc.subjectaldosterone
dc.subjectheart failure
dc.subjectleft ventricular systolic dysfunction
dc.subjecteplerenone
dc.subjectEPHESUS
dc.subjectACUTE MYOCARDIAL-INFARCTION
dc.subjectIMPLANTABLE CARDIOVERTER-DEFIBRILLATOR
dc.subjectSELECTIVE ALDOSTERONE BLOCKER
dc.subjectHEART-RATE-VARIABILITY
dc.subjectOXIDATIVE STRESS
dc.subjectSPIRONOLACTONE
dc.subjectFAILURE
dc.subjectDYSFUNCTION
dc.subjectPREVENTS
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleEvaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction <= 30%
dc.typeartículo
dc.volumen8
sipa.codpersvinculados98700
sipa.indexWOS
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
European J of Heart Fail - 2006 - Pitt - Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left.pdf
Size:
213.95 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas